Role of adjuvant chemotherapy in the management of stage IC ovarian granulosa cell tumors

Abstract

Objective The aim of the present study was to investigate the patterns of use and prognostic significance of adjuvant chemotherapy (CT) for patients with stage IC ovarian granulosa cell tumors (GCTs). Methods We identified patients with stage IC GCTs diagnosed between 2004 and 2015 in the National Cancer Data Base (NCDB). Logistic regression was performed to identify variables independently associated with chemotherapy administration. Overall survival (OS) was evaluated for patients diagnosed between 2004 and 2014 following generation of Kaplan-Meier curves and compared with the log-rank test. A Cox model was constructed to control for known confounders. Results A total of 492 patients with stage IC GCTs were identified, of which 166 (33.7%) received CT. Tumor size > = 10 cm (OR: 1.85, 95% CI: 1.21, 2.82) was independently associated with the administration of CT. There was no difference in OS between patients who did ( n = 145) and did not ( n = 282) receive CT, p = 0.52; 5-yr OS rates were 93.7% and 91.6% respectively. After controlling for patient age (<50 vs ≥50 years), tumor size and performance of lymphadenectomy (LND), the administration of CT was not associated with a survival benefit (HR: 1.07, 95% CI: 0.52, 2.21). Conclusions Approximately one in three patients with stage IC GCTs received CT in the NCDB, however CT was not associated with a survival benefit.

Development and Validation of a Prognostic Prediction Model for Postoperative Ovarian Sex Cord-Stromal Tumor Patients

“…It may also due to the preselection of patients or ineffective chemotherapeutic regimens. In addition, multiple studies have found that patients with stage I and II disease did not benefit from postoperative chemotherapy, even if they had high-risk characteristics [ 34 , 35 ]. This finding suggests that surgery is sufficient for indolent early-stage cancer, and that chemotherapy can impair quality of life by serious adverse effects.…”

In Vitro Systematic Drug Testing Reveals Carboplatin, Paclitaxel, and Alpelisib as a Potential Novel Combination Treatment for Adult Granulosa Cell Tumors

“…However, the response rates remain low and benefits are only expected in a subset of patients. Moreover, several recent studies found no survival benefit after treatment with either chemotherapy or endocrine therapy in AGCT patients, emphasizing the need for novel treatment options [14][15][16][17][18][19].…”

Ovarielle Keimstrang-Stromatumoren

“…Hier ist die Adnexexstirpation wahrscheinlich ausreichend. Eine adjuvante Chemotherapie hat keinen Nutzen [35,36]. G2oder G3-SLCT und solche mit heterologen Elementen oder retiformen Komponenten zeigen häufig ein malignes Verhalten [11].…”